(Q35614106)

9 August 2017

title

Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions (English)

1 reference

9 August 2017

1 reference

1 reference

David Feifel

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

9 August 2017

published in

Neuropsychopharmacology

1 reference

9 August 2017

volume

37

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

304-305

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2011.184

9 August 2017

exact match

0 references

cites work

Peripheral oxytocin is associated with reduced symptom severity in schizophrenia

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3238071

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients

12 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3238071

The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans

12 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3238071

Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating

12 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNPP.2011.184

Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNPP.2011.184

21 January 2018

Identifiers

DOI

10.1038/NPP.2011.184

1 reference

9 August 2017

1 reference

9 August 2017

1 reference